Animal health industry rankings 2017: One big Boehringer-sized change masks ongoing vibrancy across big players
This year's rankings are dominated by the changes brought by Boehringer Ingelheim's acquisition of Merial. However, the fiscal 2017 standings highlight many more trends and movements. Animal Pharm editor Joseph Harvey looks at a largely positive year for the top lines of animal health's leading players.
While last year saw a double-digit bonanza for the animal health sector's leaders, 2016 was slightly more subdued. Nevertheless, do not be fooled, says Animal Pharm editor Joseph Harvey. The industry is in a healthy position and change is in the air. Growth rates may be stymied by new antibiotic regulations but necessity is the mother of invention.
More than half of the top 20 animal health companies recorded double-digit sales growth in fiscal 2015. Only a handful of firms did not achieve growth rates of over 5%, as exchange rates stymied the two biggest businesses. Animal Pharm editor Joseph Harvey investigates a year of multiple topline successes.
Elanco's acquisition-fuelled charge towards the top of the industry rankings not only has the top three firms looking over their shoulders but it has also rid the top 20 of two significant players. Animal Pharm Editor Joseph Harvey takes a look at the shifting sands beneath the sector's top players.
The takeaway theme of the latest animal health industry rankings is stunted sales growth being tackled by large-scale corporate changes.
Of all the leading animal health companies, Elanco achieved the highest revenue growth rate in 2012. Other success stories belonged to Virbac and Ceva, as some of the big players recorded growth below industry average. Senior reporter Joseph Harvey analyzes a year in which Novartis slumped and Pfizer ended an era quietly.
The biggest positional change in Animal Pharm’s animal health industry sales ranking for 2011 reflected the continuing rise of Elanco. Pfizer, for much of 2010-11 the focus of demerger speculation, was boosted by the addition of Alpharma and turned in another impressive operational performance. Most of the leading companies did likewise. Informa principal analyst Ashley Yeo digests the figures
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.